Wall Street

Pfizer Cuts Covid-Drug Outlook – Bad News for This Growth Stock

Published by
The Street

By Maxx Chatsko The decision forced a key supplier for a drug component to reduce 2022 guidance. Pfizer (PFE) – Get Pfizer Inc. Report may have used artificial intelligence and advanced computational modeling to more quickly develop Paxlovid, but that never guaranteed commercial success. Indeed, the pandemic star may have quietly hinted at reduced expectations for its oral antiviral pill. That’s bad news for a popular growth stock. Codexis (CDXS) – Get Codexis Inc. Report announced a restructured supply agreement for a key ingredient for Paxlovid. Specifically, Codexis supplies an enzyme that …

Read More

Share this Story
Load More Related Articles
Load More In Wall Street